BACKGROUND In colorectal cancer, CDX2 expression is lost in approximately 20% of cases and associated with poor outcome. Here, we aim to validate the clinical impact of CDX2 and investigate the role of promoter methylation and histone deacetylation in CDX2 repression and restoration. METHODS CDX2 immunohistochemistry was performed on multi-punch tissue microarrays (n = 637 patients). Promoter methylation and protein expression investigated on 11 colorectal cancer cell lines identified two CDX2 low expressors (SW620, COLO205) for treatment with decitabine (DNA methyltransferase inhibitor), trichostatin A (TSA) (general HDAC inhibitor), and LMK-235 (specific HDAC4 and HDAC5 inhibitor). RNA and protein levels were assessed. HDAC5 recr...
Background and objective: Colorectal cancer is a multi-factorial disease process, with etiology enco...
Immune checkpoint inhibitors (ICIs) showed efficacy in metastatic colorectal cancer (mCRC) with mism...
Background: Survival of metastatic colorectal cancer (mCRC) patients has improved, but mainly for tr...
Abstract Background In colorectal cancer, CDX2 expression is lost in approximately 20% of cases and ...
Colorectal cancer is a heterogeneous disease at the histomorphological, clinical and molecular level...
Current risk factors in stage II colorectal carcinoma are insufficient to guide treatment decisions....
Background: Approximately 20% of all colorectal cancers are hypothesized to arise from the “serrated...
Caudal type homeobox 2 (CDX2) has been well-established as a diagnostic marker for colorectal cancer...
We aimed to refine the value of CDX2 as an independent prognostic and predictive biomarker in colore...
Background: Approximately 20% of all colorectal cancers are hypothesized to arise from the serrated ...
AbstractHomeodomain-only protein X (HOPX)-β promoter methylation was recently shown to be frequent i...
Purpose: Caudal-type homeobox transcription factor 2 (CDX2) is expressed in the nucleus of the intes...
Expression of the homeobox protein CDX1 is lost or reduced in a significant proportion of colorectal...
The CDX1 homeobox gene encodes a transcription factor specifically expressed in normal intestinal an...
Research on DNA methylation offers great potential for the identification of biomarkers that can be ...
Background and objective: Colorectal cancer is a multi-factorial disease process, with etiology enco...
Immune checkpoint inhibitors (ICIs) showed efficacy in metastatic colorectal cancer (mCRC) with mism...
Background: Survival of metastatic colorectal cancer (mCRC) patients has improved, but mainly for tr...
Abstract Background In colorectal cancer, CDX2 expression is lost in approximately 20% of cases and ...
Colorectal cancer is a heterogeneous disease at the histomorphological, clinical and molecular level...
Current risk factors in stage II colorectal carcinoma are insufficient to guide treatment decisions....
Background: Approximately 20% of all colorectal cancers are hypothesized to arise from the “serrated...
Caudal type homeobox 2 (CDX2) has been well-established as a diagnostic marker for colorectal cancer...
We aimed to refine the value of CDX2 as an independent prognostic and predictive biomarker in colore...
Background: Approximately 20% of all colorectal cancers are hypothesized to arise from the serrated ...
AbstractHomeodomain-only protein X (HOPX)-β promoter methylation was recently shown to be frequent i...
Purpose: Caudal-type homeobox transcription factor 2 (CDX2) is expressed in the nucleus of the intes...
Expression of the homeobox protein CDX1 is lost or reduced in a significant proportion of colorectal...
The CDX1 homeobox gene encodes a transcription factor specifically expressed in normal intestinal an...
Research on DNA methylation offers great potential for the identification of biomarkers that can be ...
Background and objective: Colorectal cancer is a multi-factorial disease process, with etiology enco...
Immune checkpoint inhibitors (ICIs) showed efficacy in metastatic colorectal cancer (mCRC) with mism...
Background: Survival of metastatic colorectal cancer (mCRC) patients has improved, but mainly for tr...